Marketing labels do not describe operational capability.
Terms such as “medical,” “clinical,” “retreat,” or “detox” can be used inconsistently. For people comparing Mexican ibogaine provider types, a structured register should separate what a provider calls itself from what can be documented about staffing, equipment, screening, escalation planning, and oversight.
That distinction matters because ibogaine has been associated with cardiac concerns, including QT interval changes. The FDA’s drug-interactions reference is one reason a list of current medicines and QT-prolonging medications belongs in a documented screening conversation, rather than in a promotional promise.
“Classification is provisional when evidence is partial, conflicting, dated, or unavailable for independent review.”
Use the broader Mexican Ibogaine Directory register alongside this typology to keep the focus on comparable evidence rather than individual narratives.